OncoMed(美國)

OncoMed

美國OncoMedwww.oncomed.comOncoMed制藥是一個(gè)臨床階段的公司發(fā)現(xiàn)并開發(fā)新型療法，針對癌癥干細(xì)胞，細(xì)胞認(rèn)為是能夠驅(qū)動(dòng)腫瘤生長，復(fù)發(fā)和轉(zhuǎn)移。癌癥干細(xì)胞研究的，該公司已建立了癌癥干細(xì)胞的蛋白質(zhì)抗體庫的實(shí)體腫瘤，如胰腺癌，乳腺癌，腸癌和肺癌的治療。OncoMed已推進(jìn)到診所指，OMP-21M18-59R5，OMP的，和OMP-18R5，該目標(biāo)的關(guān)鍵癌癥干細(xì)胞的信號包括Notch和 Wnt信號通路的三防癌干細(xì)胞的單克隆抗體。此外，OncoMed的管道包括了一些新的臨床前候選產(chǎn)品，針對多個(gè)驗(yàn)證癌癥干細(xì)胞的途徑。OncoMed與拜耳醫(yī)藥保健制藥和葛蘭素史克公司已形成戰(zhàn)略聯(lián)盟。私人持有，OncoMed的投資者包括：TheVerticalGroup,MorgenthalerVentures,Phase4Ventures,DelphiVentures,AdamsStreetPartners,DeNovoVentures,BayPartnersandGlaxoSmithKline.OncoMedPharmaceuticalsisaclinical-stagecompanythatdiscoversanddevelopsnoveltherapeuticstargetingcancerstemcells,thecellsbelievedtobecapableofdrivingtumorgrowth,recurrenceandmetastasis.Aleaderincancerstemcellresearch,thecompanyhasestablishedalibraryofantibodiestocancerstemcellproteinsforthetreatmentofsolidtumorssuchaspancreatic,breast,colorectalandlungcancers.OncoMedhasadvancedthreeanti-cancerstemcellmonoclonalantibod